BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Foulkes WD, Shuen AY. In brief: BRCA1 and BRCA2. J Pathol 2013;230:347-9. [PMID: 23620175 DOI: 10.1002/path.4205] [Cited by in Crossref: 60] [Cited by in F6Publishing: 42] [Article Influence: 7.5] [Reference Citation Analysis]
Number Citing Articles
1 Angeli D, Salvi S, Tedaldi G. Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test? Int J Mol Sci 2020;21:E1128. [PMID: 32046255 DOI: 10.3390/ijms21031128] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 17.0] [Reference Citation Analysis]
2 Muendlein A, Rohde BH, Gasser K, Haid A, Rauch S, Kinz E, Drexel H, Hofmann W, Schindler V, Kapoor R, Decker T, Lang AH. Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer. J Cancer Res Clin Oncol 2015;141:2005-12. [PMID: 25971625 DOI: 10.1007/s00432-015-1986-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
3 Dong J, Zhang T, Ren Y, Wang Z, Ling CC, He F, Li GC, Wang C, Wen B. Inhibiting DNA-PKcs in a non-homologous end-joining pathway in response to DNA double-strand breaks. Oncotarget 2017;8:22662-73. [PMID: 28186989 DOI: 10.18632/oncotarget.15153] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
4 Liu X, Dong R, Jiang Z, Wei Y, Li Y, Wei L, Sun H, Li Y, Yang N, Yang Q, Liu Z, Kong B. MDC1 promotes ovarian cancer metastasis by inducing epithelial-mesenchymal transition. Tumor Biol 2015;36:4261-9. [DOI: 10.1007/s13277-015-3063-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
5 Pilgrim SM, Pain SJ, Tischkowitz MD. Opportunities and challenges of next-generation DNA sequencing for breast units. Br J Surg 2014;101:889-98. [PMID: 24676784 DOI: 10.1002/bjs.9458] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
6 Kwee JK. A paradoxical chemoresistance and tumor suppressive role of antioxidant in solid cancer cells: a strange case of Dr. Jekyll and Mr. Hyde. Biomed Res Int 2014;2014:209845. [PMID: 24800215 DOI: 10.1155/2014/209845] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
7 Wang Z, Yin H, Zhang Y, Feng Y, Yan Z, Jiang X, Bukhari I, Iqbal F, Cooke HJ, Shi Q. miR-214-mediated downregulation of RNF8 induces chromosomal instability in ovarian cancer cells. Cell Cycle 2014;13:3519-28. [PMID: 25483088 DOI: 10.4161/15384101.2014.958413] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
8 Zhou J, Kang Y, Chen L, Wang H, Liu J, Zeng S, Yu L. The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor Agents. Front Pharmacol. 2020;11:343. [PMID: 32265714 DOI: 10.3389/fphar.2020.00343] [Cited by in Crossref: 37] [Cited by in F6Publishing: 29] [Article Influence: 37.0] [Reference Citation Analysis]
9 Drummond BE, Wingert RA. Scaling up to study brca2: the zeppelin zebrafish mutant reveals a role for brca2 in embryonic development of kidney mesoderm. Cancer Cell Microenviron 2018;5:e1630. [PMID: 29707605 DOI: 10.14800/ccm.1630] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
10 Tsigelny IF, Kouznetsova VL, Lian N, Kesari S. Molecular mechanisms of OLIG2 transcription factor in brain cancer. Oncotarget 2016;7:53074-101. [PMID: 27447975 DOI: 10.18632/oncotarget.10628] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
11 Mesquita KA, Ali R, Doherty R, Toss MS, Miligy I, Alblihy A, Dorjsuren D, Simeonov A, Jadhav A, Wilson DM 3rd, Hickson I, Tatum NJ, Rakha EA, Madhusudan S. FEN1 Blockade for Platinum Chemo-Sensitization and Synthetic Lethality in Epithelial Ovarian Cancers. Cancers (Basel) 2021;13:1866. [PMID: 33919707 DOI: 10.3390/cancers13081866] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Paltsev M, Kiselev V, Muyzhnek E, Drukh V, Kuznetsov I, Pchelintseva O. Comparative preclinical pharmacokinetics study of 3,3’-diindolylmethane formulations: is personalized treatment and targeted chemoprevention in the horizon? EPMA J. 2013;4:25. [PMID: 24325835 DOI: 10.1186/1878-5085-4-25] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
13 Abdel-Fatah TM, Arora A, Moseley PM, Perry C, Rakha EA, Green AR, Chan SY, Ellis IO, Madhusudan S. DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers. Oncotarget 2015;6:21964-78. [PMID: 26267318 DOI: 10.18632/oncotarget.4157] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
14 Zhang H, Li L, Wang Y, Yin CC, Xie Y, Liu X, Ding H, Tian Z, Shen J, He L, Xia M, Ma X, Wu L. Functional analysis of BRCT missense mutations in BRCA1-mutated Chinese Han familial breast cancer. Oncol Lett 2017;14:5839-44. [PMID: 29113215 DOI: 10.3892/ol.2017.7003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Girolimetti G, Perrone AM, Santini D, Barbieri E, Guerra F, Ferrari S, Zamagni C, De Iaco P, Gasparre G, Turchetti D. BRCA-associated ovarian cancer: from molecular genetics to risk management. Biomed Res Int 2014;2014:787143. [PMID: 25136623 DOI: 10.1155/2014/787143] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
16 Boldrin E, Rumiato E, Fassan M, Cappellesso R, Rugge M, Chiarion-Sileni V, Ruol A, Alfieri R, Cagol M, Castoro C, Amadori A, Saggioro D. Genetic features of metachronous esophageal cancer developed in Hodgkin's lymphoma or breast cancer long-term survivors: an exploratory study. PLoS One 2015;10:e0117070. [PMID: 25611972 DOI: 10.1371/journal.pone.0117070] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
17 Pettapiece-Phillips R, Narod SA, Kotsopoulos J. The role of body size and physical activity on the risk of breast cancer in BRCA mutation carriers. Cancer Causes Control 2015;26:333-44. [PMID: 25579073 DOI: 10.1007/s10552-014-0521-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
18 Lohse I, Borgida A, Cao P, Cheung M, Pintilie M, Bianco T, Holter S, Ibrahimov E, Kumareswaran R, Bristow RG, Tsao MS, Gallinger S, Hedley DW. BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts. Br J Cancer. 2015;113:425-432. [PMID: 26180923 DOI: 10.1038/bjc.2015.220] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 7.5] [Reference Citation Analysis]
19 Lohse I, Borgida A, Cao P, Cheung M, Pintilie M, Bianco T, Holter S, Ibrahimov E, Kumareswaran R, Bristow RG. BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts. Br J Cancer. 2015;113:425-432. [PMID: 26180923 DOI: 10.1038/ bjc.2015.220] [Reference Citation Analysis]
20 Eccles BK, Copson ER, Cutress RI, Maishman T, Altman DG, Simmonds P, Gerty SM, Durcan L, Stanton L, Eccles DM, Eccles D, Simmonds P, Altman DG, Pharoah P, Warren R, Gilbert F, Jones L, Eeles R, Evans DGR, Hanby A, Thompson A, Hodgson S, Hammad H, Lakhani S. Family history and outcome of young patients with breast cancer in the UK (POSH study). British Journal of Surgery 2015;102:924-35. [DOI: 10.1002/bjs.9816] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
21 Roberts J, Ronn R, Tallon N, Holzer H. Fertility preservation in reproductive-age women facing gonadotoxic treatments. Curr Oncol 2015;22:e294-304. [PMID: 26300680 DOI: 10.3747/co.22.2334] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
22 Li Y, Zhou X, Liu J, Yin Y, Yuan X, Yang R, Wang Q, Ji J, He Q. Differentially expressed genes and key molecules of BRCA1/2-mutant breast cancer: evidence from bioinformatics analyses. PeerJ 2020;8:e8403. [PMID: 31998560 DOI: 10.7717/peerj.8403] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
23 Vallard A, Rancoule C, Guy JB, Espenel S, Sauvaigo S, Rodriguez-Lafrasse C, Magné N. [Biomarkers of radiation-induced DNA repair processes]. Bull Cancer 2017;104:981-7. [PMID: 29132682 DOI: 10.1016/j.bulcan.2017.09.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
24 Acharya UR, Molinari F, Sree SV, Swapna G, Saba L, Guerriero S, Suri JS. Ovarian Tissue Characterization in Ultrasound: A Review. Technol Cancer Res Treat 2015;14:251-61. [DOI: 10.1177/1533034614547445] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
25 Lobo M, López-Tarruella S, Luque S, Lizarraga S, Flores-Sánchez C, Bueno O, Solera J, Jerez Y, Del Val RG, Palomero MI, Cebollero M, Echavarría I, Torres G, Martín M, Márquez-Rodas I. Evaluation of Breast Cancer Patients with Genetic Risk in a University Hospital: Before and After the Implementation of a Heredofamilial Cancer Unit. J Genet Couns 2018;27:854-62. [PMID: 29247312 DOI: 10.1007/s10897-017-0187-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
26 Xie Y, Jiang Y, Yang XB, Wang AQ, Zheng YC, Wan XS, Sang XT, Wang K, Zhang DD, Xu JJ, Li FG, Zhao HT. Response of BRCA1-mutated gallbladder cancer to olaparib: A case report. World J Gastroenterol 2016;22:10254-9. [PMID: 28028375 DOI: 10.3748/wjg.v22.i46.10254] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
27 González-rivera M, Lobo M, López-tarruella S, Jerez Y, del Monte-millán M, Massarrah T, Ramos-medina R, Ocaña I, Picornell A, Garzón SS, Pérez-carbornero L, García-saenz JA, Gómez H, Moreno F, Márquez-rodas I, Fuentes H, Martin M. Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial. Breast Cancer Res Treat 2016;156:507-15. [DOI: 10.1007/s10549-016-3792-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
28 Chandrasekharappa SC, Chinn SB, Donovan FX, Chowdhury NI, Kamat A, Adeyemo AA, Thomas JW, Vemulapalli M, Hussey CS, Reid HH, Mullikin JC, Wei Q, Sturgis EM. Assessing the spectrum of germline variation in Fanconi anemia genes among patients with head and neck carcinoma before age 50. Cancer 2017;123:3943-54. [PMID: 28678401 DOI: 10.1002/cncr.30802] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
29 Kohn EC, Ivy SP. Confronting the Care Delivery Challenges Arising from Precision Medicine. Front Oncol 2016;6:106. [PMID: 27200294 DOI: 10.3389/fonc.2016.00106] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
30 Ding L, Kim HJ, Wang Q, Kearns M, Jiang T, Ohlson CE, Li BB, Xie S, Liu JF, Stover EH, Howitt BE, Bronson RT, Lazo S, Roberts TM, Freeman GJ, Konstantinopoulos PA, Matulonis UA, Zhao JJ. PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. Cell Rep 2018;25:2972-2980.e5. [PMID: 30540933 DOI: 10.1016/j.celrep.2018.11.054] [Cited by in Crossref: 161] [Cited by in F6Publishing: 136] [Article Influence: 80.5] [Reference Citation Analysis]
31 Pan Y, Jia LP, Liu Y, Han Y, Li Q, Zou Q, Zhang Z, Huang J, Deng Q. A novel signature of two long non-coding RNAs in BRCA mutant ovarian cancer to predict prognosis and efficiency of chemotherapy. J Ovarian Res 2020;13:112. [PMID: 32950050 DOI: 10.1186/s13048-020-00712-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
32 Dhir A, Li R, Li G, Dean J, Robin NH, Alva E. Simultaneous osteosarcoma and renal cell carcinoma with BRCA1 mutation in a young male adult with prior oligodendroglioma. Pediatr Blood Cancer 2020;67:e28116. [PMID: 31850619 DOI: 10.1002/pbc.28116] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
33 Sénéchal C, Rousset-Jablonski C. [Should a systematic fertility preservation be proposed to healthy women carrying a BRCA1/2 mutation?]. Gynecol Obstet Fertil 2015;43:800-5. [PMID: 26476890 DOI: 10.1016/j.gyobfe.2015.09.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
34 Xie Z, Zhou Y, Zhao W, Jiao H, Chen Y, Yang Y, Li Z. Identification of novel PARP-1 inhibitors: Drug design, synthesis and biological evaluation. Bioorganic & Medicinal Chemistry Letters 2015;25:4557-61. [DOI: 10.1016/j.bmcl.2015.08.060] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
35 Li L, Zhang J, Weng X, Wen G. Genetic variations in monocyte chemoattractant protein-1 and susceptibility to ovarian cancer. Tumour Biol 2015;36:233-8. [PMID: 25234717 DOI: 10.1007/s13277-014-2619-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
36 Godone RLN, Leitão GM, Araújo NB, Castelletti CHM, Lima-Filho JL, Martins DBG. Clinical and molecular aspects of breast cancer: Targets and therapies. Biomed Pharmacother 2018;106:14-34. [PMID: 29945114 DOI: 10.1016/j.biopha.2018.06.066] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 8.3] [Reference Citation Analysis]
37 Baert A, Depuydt J, Van Maerken T, Poppe B, Malfait F, Storm K, van den Ende J, Van Damme T, De Nobele S, Perletti G, De Leeneer K, Claes KB, Vral A. Increased chromosomal radiosensitivity in asymptomatic carriers of a heterozygous BRCA1 mutation. Breast Cancer Res 2016;18:52. [PMID: 27184744 DOI: 10.1186/s13058-016-0709-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
38 Lee PS, Fang J, Jessop L, Myers T, Raj P, Hu N, Wang C, Taylor PR, Wang J, Khan J, Jasin M, Chanock SJ. RAD51B Activity and Cell Cycle Regulation in Response to DNA Damage in Breast Cancer Cell Lines. Breast Cancer (Auckl) 2014;8:135-44. [PMID: 25368520 DOI: 10.4137/BCBCR.S17766] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
39 Ossa CA, Torres D. Founder and Recurrent Mutations in BRCA1 and BRCA2 Genes in Latin American Countries: State of the Art and Literature Review. Oncologist 2016;21:832-9. [PMID: 27286788 DOI: 10.1634/theoncologist.2015-0416] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 8.2] [Reference Citation Analysis]
40 Mattissek C, Teis D. The role of the endosomal sorting complexes required for transport (ESCRT) in tumorigenesis. Mol Membr Biol 2014;31:111-9. [PMID: 24641493 DOI: 10.3109/09687688.2014.894210] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
41 Koulouras G, Frith MC. Significant non-existence of sequences in genomes and proteomes. Nucleic Acids Res 2021;49:3139-55. [PMID: 33693858 DOI: 10.1093/nar/gkab139] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Mao C, Zeng X, Zhang C, Yang Y, Xiao X, Luan S, Zhang Y, Yuan Y. Mechanisms of Pharmaceutical Therapy and Drug Resistance in Esophageal Cancer. Front Cell Dev Biol 2021;9:612451. [PMID: 33644048 DOI: 10.3389/fcell.2021.612451] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]